- Home
- NVS vs MRK Comparison
NVS vs MRK Comparison
Compare NVS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | MRK |
|---|---|---|
| Founded | 1895 | 2000 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.8B | 260.2B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVS | MRK |
|---|---|---|
| Price | $132.26 | $99.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $118.00 | $109.13 |
| AVG Volume (30 Days) | 1.8M | ★ 15.8M |
| Earning Date | 01-30-2026 | 10-30-2025 |
| Dividend Yield | 1.96% | ★ 3.39% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | 7.30 | ★ 7.56 |
| Revenue | $56,372,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $9.33 | $1.97 |
| Revenue Next Year | $2.75 | $4.96 |
| P/E Ratio | $18.16 | ★ $13.27 |
| Revenue Growth | ★ 12.88 | 1.68 |
| 52 Week Low | $96.06 | $73.31 |
| 52 Week High | $134.24 | $105.84 |
Technical Indicators
Market Signals| Indicator | NVS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 59.78 |
| Support Level | $130.46 | $96.06 |
| Resistance Level | $133.84 | $99.85 |
| Average True Range (ATR) | 1.68 | 2.46 |
| MACD | 0.13 | -0.70 |
| Stochastic Oscillator | 75.78 | 43.03 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).